Invention Grant
- Patent Title: Neridronic acid for treating complex regional pain syndrome
-
Application No.: US15703891Application Date: 2017-09-13
-
Publication No.: US09931352B2Publication Date: 2018-04-03
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Maschoff Brennan Laycock Gilmore
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/663 ; A61K45/06 ; A61K9/00 ; A61K9/20 ; A61K31/573 ; A61K31/675
Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
Public/Granted literature
- US20180000848A1 Osteoclast Inhibitors for Knee Conditions Public/Granted day:2018-01-04
Information query
